1. Home
  2. SSRM vs PCVX Comparison

SSRM vs PCVX Comparison

Compare SSRM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SSR Mining Inc.

SSRM

SSR Mining Inc.

HOLD

Current Price

$31.85

Market Cap

6.5B

Sector

Industrials

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$58.87

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSRM
PCVX
Founded
1946
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.0B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
SSRM
PCVX
Price
$31.85
$58.87
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$32.74
$88.25
AVG Volume (30 Days)
3.2M
945.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
243.41
N/A
EPS
N/A
N/A
Revenue
$1,629,637,000.00
N/A
Revenue This Year
$56.48
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
63.68
N/A
52 Week Low
$15.99
$29.87
52 Week High
$36.52
$65.00

Technical Indicators

Market Signals
Indicator
SSRM
PCVX
Relative Strength Index (RSI) 62.26 58.47
Support Level $28.41 $52.18
Resistance Level $33.66 $62.54
Average True Range (ATR) 1.31 2.40
MACD 0.71 0.38
Stochastic Oscillator 85.52 82.24

Price Performance

Historical Comparison
SSRM
PCVX

About SSRM SSR Mining Inc.

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: